BioWorld

June 23, 2003

Genentech, Tanox Receive FDA Approval For Asthma Therapeutic

Genentech Inc. and partners Tanox Inc. and Novartis Pharma AG said late Friday the FDA approved Xolair, a first-in-class monoclonal antibody for moderate to severe persistent asthma in adults and adolescents. (BioWorld Today) Read More

President Bush Among Headliners At BIO Conference In Washington

Genetically Tinkered Coffee Beans Produce Decaffeinated Brew Minus Alkaloid's Undesirable Side Effects

Discovery Laboratories Raises $27.M To Advance Surfactant

Hollis-Eden Raises $15M Via Private Placement Of Stock

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...